Recently, preclinical data reported the superiority of Tscm CAR-T cells (CD4+CD8+CD62L+CD45RA+) with respect to bulk T cells (CD4+CD8+) in terms of antitumor activity and expansion capacity in xenograft mouse models of leukemia [63] and lymphoma [64]. Here, CD8A is linked to leukemia.